Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $70 price target on Ultragenyx after its Q3 update marked the first full quarter of sales of Crysvita. The analyst notes that the launch has continued its momentum with other positive also coming from Mepsevii and its approval in all 28 E.U. countries and Brazil. Raymond further states that a number of near-term catalysts remain for Ultragenyx in 2018, such as the initial update on DTX401 in Glycogen storage disease, keeping a constructive view on the stock.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.